VPC
IONS icon

Vestal Point Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Vestal Point Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,075,000
Closed -$70.3M – 96
2025
Q3 		$70.3M Buy
1,075,000
+575,000
+115% +$28.1M 3.18% 9
2025
Q2 		$19.8M Buy
+500,000
New +$16.4M 1.04% 36
2025
Q1 		– Sell
-595,000
Closed -$20.8M – 71
2024
Q4 		$20.8M Buy
+595,000
New +$22.2M 1.23% 30

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vestal Point Capital's IONS Position: Q4 2025 in Review

Vestal Point Capital sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 1,075,000 shares — an estimated $70.3M sold.

Vestal Point Capital first reported a position in IONS in Q4 2024 and held it in 3 quarters. The position peaked at $70.3M in Q3 2025. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

  • Vestal Point Capital reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Vestal Point Capital sold 1,075,000 Ionis Pharmaceuticals shares in Q4 2025, an estimated $70.3M.
  • Vestal Point Capital first reported a position in Ionis Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Vestal Point Capital's Ionis Pharmaceuticals position peaked at $70.3M in Q3 2025.
  • 491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.